Company intelligence / Profile preview
Respirogen
Boulder, Colorado, United Statesrespirogen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Respirogen has developed a lipid-based oxygen microbubble technology designed for systemic oxygen delivery independent of lung function. Preclinical data demonstrated that OMBs could keep rats alive indefinitely despite severely compromised lungs. As of late 2021, the company was preparing for first-in-human clinical trials.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Oxygen microbubbles (OMB)enhanced oxygen compositions
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Respirogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Respirogen.